is uncertain. Among women at risk of late preterm delivery, we sought to determine whether time interval (TI) between betamethasone and delivery is associated with neonatal adverse respiratory outcomes. STUDY DESIGN: This is a secondary analysis of a multicenter randomized trial to determine the effects of betamethasone in women at risk for late preterm delivery. The inclusion criteria for our analysis were singletons with no major anomaly, receiving betamethasone, with calculable TI between administration of last betamethasone dose and delivery. TI categories were: 1) 48 hours; 2) > 48 and 168 hours, and; 3) > 168 hours (7 days). Primary outcome was neonatal respiratory outcomes among the 3 TI groups. Primary and secondary outcomes are defined in the tables. Multivariable Poisson regression models with robust error variance were used to determine the association between TI and neonatal outcomes, while adjusting for confounders. Adjusted relative risk (aRR) with 95% confidence intervals (CI) were calculated, using TI > 48 and 168 hours as the referent group. RESULTS: Of the 2,831 women in the parent trial, 1,414 (50.7%) met our inclusion criteria. While 68.5% delivered in 48 hours, 15.3% were born > 48 and 168 hours and 16.2% at > 168 hrs. Factors significantly different among the three groups include: nulliparity, pre-pregnancy BMI, hypertensive disease, premature preterm rupture of membranes, number of betamethasone doses (1 versus 2), preterm delivery (gestational age < 37 weeks), labor type, and route of delivery. Among women who received betamethasone, the primary outcome was significantly less if delivery occurred > 168 hours, compared to > 48 and 168 hrs. Severe respiratory complications were also significantly lower if delivery occurred > 168 hours, compared to > 48 and 168 hours. (Table) CONCLUSION: Even when adjusted for rate of preterm birth, among women at risk for late preterm birth, the lowest rate of neonatal respiratory complication is when delivery occurred beyond 168 hrs (7 days).
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The risk of severe prematurity in asymptomatic women presenting with short cervix in early viability 
OBJECTIVE:
We set out to investigate the likelihood of delivery in the severe preterm period (< 32 weeks) in asymptomatic women based on the severity of the cervical length (CL) measurement.
STUDY DESIGN:
We performed a retrospective, single center, cohort study of asymptomatic women presenting with a short cervix (CL 25mm) between 23 and 28 weeks' gestation. The study period spread from January 2015 to March 2018. Demographic information as well as risk factors for spontaneous PTB was collected. Cases were divided into 4 groups based on the severity of their CL measurement ( 10mm, 11-15mm, 16-20mm, 21-25mm) . The primary outcome was delivery in the severe preterm period (< 32 weeks). Secondary outcomes included preterm delivery (<37 weeks), and gestational age at delivery. Fisher's exact test was employed for statistical analysis. The Wilcoxon test for differences in survival time was used to compare GA at delivery among the 4 CL groups with data stratified based on GA at presentation. RESULTS: 126 pregnancies met inclusion criteria. Baseline characteristics were similar among all four groups. The results are presented in Table 1 . Although an asymptomatic short cervix was associated with an increased risk for severe PTB (< 32 weeks), the prevalence was disproportionally higher in women with a CL 10mm compared to those with a longer CL (p ¼ < 0.001). 
CONCLUSION:
Of asymptomatic women presenting with a short cervix in early viability, those with a CL 10mm are at a significantly higher risk for severe PTB. This information may be helpful when counselling asymptomatic women with short cervix on risk of delivery in the severe preterm period when prematurity-related complications are of major concern.
466 The risk of anticipated delivery in asymptomatic women presenting with short cervix in early viability Eurofins NTD, Melville, NY OBJECTIVE: While it is known that an asymptomatic short cervical length (CL) is an independent risk factor for spontaneous preterm birth (sPTB), it is unclear when the delivery will take place. Subsequently, management decisions such as timing of antenatal corticosteroid (ACS) administration or hospital admission may be suboptimal. Therefore, the purpose of this study was to determine the risk of anticipated delivery in asymptomatic women presenting with a short CL in early viability. STUDY DESIGN: A retrospective cohort study of asymptomatic women with short cervix, (CL 25mm) between 23 and 28 weeks' gestation, at a single center from January 2015 to March 2018 was performed. Women with multiple gestations, fetal anomalies and cervical cerclage were excluded. Demographic information as well as risk factors for sPTB were collected. Cases were divided into 4 groups based on CL measurement ( 10mm, 11-15mm, 16-20mm, 21-25mm) . The primary outcome was time interval from presentation to delivery (Dt). Secondary outcomes included delivery within 2 weeks of presentation and gestational age (GA) at delivery. Continuous variables were compared using the Kruskal-Wallis test, while categorical variables were compared using Chi-squared or Fisher's exact test as appropriate. The Wilcoxon test for difference in survival time was used to compare GA at delivery among the 4 CL groups with data stratified based on GA at presentation. RESULTS: 126 pregnancies met inclusion criteria. Baseline characteristics were similar among all four groups. Primary and secondary outcomes are reported in Table 1 . The probability of delivery as a function of Dt is presented in Figure 1 . There was a direct correlation between shorter CL and shorter Dt (p ¼ 0.003). Regardless of the CL at presentation, delivery within 2 weeks was uncommon (1 patient; 0.8%). CONCLUSION: As expected, the risk for sPTB in asymptomatic women with short cervix increases as the CL shortens, with CL 10mm associated with the highest risk. Nevertheless, regardless of the CL, delivery within 2 weeks is highly unlikely. Therefore, we suggest that the timing of administration of ACS in this population should be delayed until additional indications are present. 
